{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:56:23Z","timestamp":1790556983387,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Genitourinary syndrome of menopause (GSM) affects a significant proportion of postmenopausal women, leading to symptoms such as vaginal dryness, irritation, dyspareunia, and urinary symptoms. Hormonal therapies are not suitable for all patients, particularly those with contraindications to hormone use. This study aims to compare the efficacy and safety of two non-hormonal therapies\u2014fractional CO\u2082 laser (CO\u2082 laser) and fractional microablative radiofrequency (MAFRF)\u2014for the treatment of GSM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This protocol describes a randomised, double-blind, non-inferiority clinical trial that will enrol 40 postmenopausal women diagnosed with GSM. Participants will be randomised to receive either fractional CO\u2082 laser or fractional microablative radiofrequency in three monthly sessions. The primary outcome will be the Vaginal Health Index Score (VHIS), assessed 30\u00a0days after the last treatment session (day 90). Secondary outcomes include sexual function, GSM symptom severity, and urinary symptoms. Follow-up assessments will be conducted at 120 and 300\u00a0days after the last session (days 180 and 365, respectively). Histological analysis of vaginal biopsies will be performed in a predefined subsample of participants as an exploratory analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study is expected to contribute to the comparative understanding of the efficacy and safety of CO\u2082 laser and MAFRF as non-hormonal therapeutic options for the treatment of GSM, potentially supporting clinical decision-making for women who are not candidates for hormonal therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Brazilian Clinical Trials Registry (ReBEC): RBR-2hgwvgy. The trial was registered retrospectively due to administrative delays in the registration process. However, no outcome data were accessed, analysed, or used to inform any decisions prior to registration, and no interim analyses were performed. Additionally, no modifications were made to the study design, outcomes, or planned analyses after the initiation of data collection. Registered on July 2, 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09865-3","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:39:55Z","timestamp":1783049995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of genitourinary syndrome of menopause with fractional CO\u2082 laser versus fractional microablative radiofrequency: study protocol for a double-blind, randomised, non-inferiority trial"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5191-6890","authenticated-orcid":false,"given":"C\u00e1ssia Caroline","family":"Garcia Dalbem Teles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-9216","authenticated-orcid":false,"given":"Catarina Maria","family":"Mesquita Garcia Dalbem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5517-0777","authenticated-orcid":false,"given":"Matheus Rodrigues","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1774-9053","authenticated-orcid":false,"given":"Nivaldo Antonio","family":"Parizotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"10","key":"9865_CR1","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","volume":"21","author":"DJ Portman","year":"2014","unstructured":"Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063\u20138. https:\/\/doi.org\/10.1097\/GME.0000000000000329.","journal-title":"Menopause"},{"issue":"3","key":"9865_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jsxm.2017.01.011","volume":"14","author":"M Krychman","year":"2017","unstructured":"Krychman M, Graham S, Bernick B, Mirkin S, Kingsberg SA. The Women\u2019s EMPOWER survey: women\u2019s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med. 2017;14(3):425\u201333. https:\/\/doi.org\/10.1016\/j.jsxm.2017.01.011.","journal-title":"J Sex Med"},{"issue":"3","key":"9865_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/13697137.2018.1446930","volume":"21","author":"S Palacios","year":"2018","unstructured":"Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286\u201391. https:\/\/doi.org\/10.1080\/13697137.2018.1446930.","journal-title":"Climacteric"},{"issue":"4","key":"9865_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/13697137.2014.899347","volume":"17","author":"S Salvatore","year":"2014","unstructured":"Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17(4):363\u20139. https:\/\/doi.org\/10.3109\/13697137.2014.899347.","journal-title":"Climacteric"},{"issue":"3","key":"9865_CR5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.maturitas.2014.12.006","volume":"80","author":"A Perino","year":"2015","unstructured":"Perino A, Cucinella G, Gugliotta G, et al. Is vaginal fractional CO\u2082 laser treatment effective in improving vaginal atrophy symptoms in postmenopausal patients? Maturitas. 2015;80(3):296\u2013301.","journal-title":"Maturitas"},{"key":"9865_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.maturitas.2017.01.012","volume":"99","author":"M Gambacciani","year":"2017","unstructured":"Gambacciani M, Palacios S. Laser therapy for the restoration of vaginal function. Maturitas. 2017;99:10\u20135. https:\/\/doi.org\/10.1016\/j.maturitas.2017.01.012.","journal-title":"Maturitas"},{"issue":"2","key":"9865_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1590\/S1679-45082017AO4051","volume":"15","author":"MF Kamilos","year":"2017","unstructured":"Kamilos MF, Borrelli GM. Radiofrequency in the treatment of genitourinary syndrome of menopause: a pilot study. Einstein (Sao Paulo). 2017;15(2):190\u20135. https:\/\/doi.org\/10.1590\/S1679-45082017AO4051.","journal-title":"Einstein (Sao Paulo)"},{"key":"9865_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2025.108737","author":"H Slongo","year":"2025","unstructured":"Slongo H, Henriques DCP, Ongaratto APN, et al. Microablative and non-ablative laser and radiofrequency treatment of genitourinary syndrome of menopause: a randomised controlled trial with four different energies. Maturitas. 2025. https:\/\/doi.org\/10.1016\/j.maturitas.2025.108737.","journal-title":"Maturitas"},{"key":"9865_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2024.108008","author":"IB Seganfredo","year":"2024","unstructured":"Seganfredo IB, Bianchi C, Tacla M, et al. Comparison of promestriene with vaginal fractional CO\u2082 laser and radiofrequency treatments of genitourinary syndrome of menopause. Maturitas. 2024. https:\/\/doi.org\/10.1016\/j.maturitas.2024.108008.","journal-title":"Maturitas"},{"key":"9865_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2024.108155","author":"GC Cantarelli","year":"2024","unstructured":"Cantarelli GC, Bianchi-Ferraro AMHM, Dedonatto C, et al. Clinical and histomorphometric evaluation of the vagina following treatment with CO2 laser, radiofrequency, and promestriene for genitourinary syndrome of menopause in breast cancer survivors on adjuvant therapy. Maturitas. 2024. https:\/\/doi.org\/10.1016\/j.maturitas.2024.108155.","journal-title":"Maturitas"},{"key":"9865_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.70563","author":"PA Torre","year":"2025","unstructured":"Torre PA, Fialho SCAV, do Icc VG, et al. Efficacy and safety of fractional microablative radiofrequency versus topical estriol in treating genitourinary syndrome of menopause: a pilot study. Int J Gynaecol Obstet. 2025. https:\/\/doi.org\/10.1002\/ijgo.70563.","journal-title":"Int J Gynaecol Obstet"},{"key":"9865_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081477","volume":"389","author":"A-W Chan","year":"2025","unstructured":"Chan A-W, Boutron I, Hopewell S, Moher D, Schulz KF, et al. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ. 2025;389:e081477. https:\/\/doi.org\/10.1136\/bmj-2024-081477.","journal-title":"BMJ"},{"issue":"1","key":"9865_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/pst.1716","volume":"15","author":"L Flight","year":"2016","unstructured":"Flight L, Julious SA. Practical guide to sample size calculations: non-inferiority and equivalence trials. Pharm Stat. 2016;15(1):80\u20139. https:\/\/doi.org\/10.1002\/pst.1716.","journal-title":"Pharm Stat"},{"issue":"9","key":"9865_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.32563","volume":"5","author":"Y Jang","year":"2022","unstructured":"Jang Y, Leung CY, Huang H. Comparison of symptom severity of genitourinary syndrome of menopause after carbon dioxide laser therapy versus vaginal estrogen therapy: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(9):e2232563. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.32563.","journal-title":"JAMA Netw Open"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09865-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09865-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09865-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:29:54Z","timestamp":1790555394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09865-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9865"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09865-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6531733\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Research Ethics Committee of Universidade Brasil under approval number 5.357.602 on 19 April 2022. Written informed consent was obtained from all participants prior to enrolment and before the performance of any study-related procedures, in accordance with applicable national and international ethical guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate {30}","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study does not include the publication of images, videos, or any information that could allow identification of individual participants. If requested, the model informed consent form may be made available.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors (CCGDT, CMGDT, MRS, and NAP) declare that they have no financial or non-financial competing interests related to this study.","order":3,"name":"Ethics","label":"Competing interests {7b}","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"585"}}